HCAT vs IBM
HCAT: A healthcare intelligence company providing AI-driven technology and professional services to help health systems derive actionable, measurable clinical and financial improvements from their data. IBM: IBM is a premier hybrid cloud and AI technology partner helping global enterprises navigate digital transformation and infrastructure modernization.
Side-by-side fundamentals
| Metric | HCAT | IBM | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $1.75 | $241.92 | |
| Market cap | $132M | $227.9B | |
| P/E as of 2026-10-20 | n/a | 21.43 | |
| Net margin FY2025, SEC XBRL | -57.2% | +15.7% | IBM higher |
| Gross margin FY2025, SEC XBRL | n/a | +58.2% | |
| Operating margin FY2025, SEC XBRL | -51.7% | n/a | |
| ROE FY2025, SEC XBRL | -72.4% | +32.4% | IBM higher |
| ROA FY2025, SEC XBRL | -35.4% | +7.0% | IBM higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 1.52 | 1.80 | HCAT lower |
| Revenue growth (YoY) FY2025, SEC XBRL | +1.5% | +7.6% | IBM higher |
| Revenue CAGR (3y) SEC XBRL | +4.0% | +3.7% | HCAT higher |
| Dividend yield as of 2026-09-03 | n/a | +2.9% | |
| Dividend streak (yrs) SEC XBRL | 0 | 10 | IBM higher |
| Beta as of 2026-09-03 | 1.33 | 0.78 | |
| 1-year return as of 2026-10-20 close | -43.9% | -14.7% | IBM higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.